NO20032181L - Anvendelse av CCI-779 som et antineoplastisk middel - Google Patents

Anvendelse av CCI-779 som et antineoplastisk middel

Info

Publication number
NO20032181L
NO20032181L NO20032181A NO20032181A NO20032181L NO 20032181 L NO20032181 L NO 20032181L NO 20032181 A NO20032181 A NO 20032181A NO 20032181 A NO20032181 A NO 20032181A NO 20032181 L NO20032181 L NO 20032181L
Authority
NO
Norway
Prior art keywords
cci
antineoplastic agent
antineoplastic
agent
neoplasms
Prior art date
Application number
NO20032181A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032181D0 (no
Inventor
Jr James Joseph Gibbons
Philip Frost
Carolyn Mary Discafani-Marro
Gary Dukart
Lisa Anne Speicher
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20032181L publication Critical patent/NO20032181L/no
Publication of NO20032181D0 publication Critical patent/NO20032181D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20032181A 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel NO20032181D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15
PCT/US2001/047324 WO2002040000A2 (fr) 2000-11-15 2001-11-13 Utilisation du cci-779 en tant qu'agent antineoplasique

Publications (2)

Publication Number Publication Date
NO20032181L true NO20032181L (no) 2003-05-14
NO20032181D0 NO20032181D0 (no) 2003-05-14

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032181A NO20032181D0 (no) 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel

Country Status (28)

Country Link
US (3) US20020091137A1 (fr)
EP (1) EP1335725B1 (fr)
JP (4) JP4472251B2 (fr)
KR (1) KR100827942B1 (fr)
CN (2) CN1678312A (fr)
AR (1) AR031341A1 (fr)
AT (1) ATE393629T1 (fr)
AU (2) AU2731302A (fr)
BR (1) BR0115323A (fr)
CA (1) CA2429020C (fr)
CY (1) CY1108109T1 (fr)
DE (1) DE60133831T2 (fr)
DK (1) DK1335725T3 (fr)
EA (1) EA007096B1 (fr)
ES (1) ES2305134T3 (fr)
HK (1) HK1058008A1 (fr)
HU (1) HUP0400521A3 (fr)
IL (2) IL155871A0 (fr)
MX (1) MXPA03004192A (fr)
NO (1) NO20032181D0 (fr)
NZ (1) NZ539668A (fr)
PL (1) PL207061B1 (fr)
PT (1) PT1335725E (fr)
SG (1) SG148031A1 (fr)
SI (1) SI1335725T1 (fr)
TW (1) TWI286074B (fr)
WO (1) WO2002040000A2 (fr)
ZA (1) ZA200304603B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PT2762140T (pt) 2001-02-19 2017-07-04 Novartis Ag Resumo
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
HUP0400006A2 (hu) * 2001-06-01 2004-04-28 Wyeth Antineopláziás kombinációs készítmények
IL162734A0 (en) * 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
AU2003280437A1 (en) * 2002-06-27 2004-01-19 Microport Medical (Shanghai) Co., Ltd. Drug eluting stent
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
KR20050084559A (ko) * 2002-09-17 2005-08-26 와이어쓰 경구 제형
CA2505416A1 (fr) 2002-11-21 2004-06-10 Wyeth Methodes de diagnostic de rcc et autres tumeurs solides
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
CA2515677A1 (fr) * 2003-02-11 2004-08-26 Wyeth Procedes pour controler in vivo des activites de medicaments
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (fr) * 2003-04-22 2007-01-24 Wyeth Combinaisons antitumorales
CA2523798A1 (fr) * 2003-04-29 2004-11-11 Wyeth Procedes de pronostic et de traitement de tumeurs solides
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
DE602004011398T2 (de) * 2004-01-08 2009-01-15 Wyeth Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
AU2006214021A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable CCI-779 tablet formulations
EP1942937A1 (fr) 2005-11-04 2008-07-16 Wyeth Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
CA2933875C (fr) * 2005-11-21 2018-06-26 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycine destinee a une utilisation comme seule substance medicamenteuse dans le traitement de tumeurs carcinoides provenant de l'intestin anterieur, l'anse vitelline ou l'intestin posterieur
PE20071067A1 (es) * 2005-12-20 2007-11-26 Wyeth Corp Composiciones de rapamicina y cci-779 y metodo para su preparacion
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
EP3142297B1 (fr) * 2007-10-03 2019-02-06 Genesis Technical Systems, Corp. Anneaux dynamiques asymétriques
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
WO2009117669A2 (fr) 2008-03-21 2009-09-24 The University Of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
PL2310011T3 (pl) 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
WO2011151704A2 (fr) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Compositions pharmaceutiques stables d'esters de rapamycine
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
AU2016311704B2 (en) * 2015-08-24 2018-11-29 Shanxi Yabao Investment Group Co., Ltd Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
EP0525960B1 (fr) 1991-06-18 1996-03-20 American Home Products Corporation Utilisation de rapamycine pour le traitement de la lymphome/leucéme des cellules T adultes
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
US20020091137A1 (en) 2002-07-11
AU2731302A (en) 2002-05-27
ES2305134T3 (es) 2008-11-01
AU2007201324A1 (en) 2007-04-19
DE60133831D1 (de) 2008-06-12
SI1335725T1 (sl) 2008-08-31
PL207061B1 (pl) 2010-10-29
ZA200304603B (en) 2004-09-13
CN1678312A (zh) 2005-10-05
PL362740A1 (en) 2004-11-02
CA2429020A1 (fr) 2002-05-23
NZ539668A (en) 2007-06-29
JP2004517065A (ja) 2004-06-10
HUP0400521A2 (hu) 2004-06-28
JP2016094444A (ja) 2016-05-26
BR0115323A (pt) 2004-02-17
KR20040029309A (ko) 2004-04-06
HUP0400521A3 (en) 2007-05-29
CA2429020C (fr) 2009-05-26
US7781446B2 (en) 2010-08-24
TWI286074B (en) 2007-09-01
AU2007201324B2 (en) 2010-11-18
WO2002040000A3 (fr) 2002-09-06
DK1335725T3 (da) 2008-06-30
CN102058588A (zh) 2011-05-18
JP4472251B2 (ja) 2010-06-02
JP2014088430A (ja) 2014-05-15
EP1335725B1 (fr) 2008-04-30
US20030153593A1 (en) 2003-08-14
EP1335725A2 (fr) 2003-08-20
EA200300566A1 (ru) 2003-10-30
KR100827942B1 (ko) 2008-05-13
NO20032181D0 (no) 2003-05-14
MXPA03004192A (es) 2003-09-22
US7189735B2 (en) 2007-03-13
HK1058008A1 (en) 2004-04-30
JP2010018620A (ja) 2010-01-28
EA007096B1 (ru) 2006-06-30
ATE393629T1 (de) 2008-05-15
CY1108109T1 (el) 2014-02-12
IL155871A0 (en) 2003-12-23
IL155871A (en) 2012-03-29
US20070142425A1 (en) 2007-06-21
AR031341A1 (es) 2003-09-17
SG148031A1 (en) 2008-12-31
PT1335725E (pt) 2008-06-19
DE60133831T2 (de) 2009-05-20
WO2002040000A2 (fr) 2002-05-23

Similar Documents

Publication Publication Date Title
NO20032181L (no) Anvendelse av CCI-779 som et antineoplastisk middel
EA200400284A1 (ru) Антинеопластические комбинации
MXPA03007140A (es) Derivados de carbolina.
DE69925133D1 (de) Pyrrolobenzodiazepine
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
NO20064130L (no) Antineoplastiske kombinasjoner av CCI-779 og rituximab
MXPA03007142A (es) Derivados de carbolina.
MXPA02012076A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
AU3938802A (en) Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
BR0210101A (pt) Combinações antineoplásticas
AR034071A1 (es) Combinaciones antineoplasicas
AR033012A1 (es) Combinaciones antineoplasicas
DE60112960D1 (de) Kondensierte pyridoindolderivate
AR029092A1 (es) Composiciones para el tratamiento del cabello
DE60127131D1 (de) Tricyclische imidazopyridine
ATE259813T1 (de) Triazolopyrimidinderivate
NO20031414D0 (no) Ny oksabispidinforbindelse som er nyttig i behandlingen av hjertearrytmier
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
ES2185605T3 (es) 2,3-dihidro-1h-5,9-dioxaciclohepta (f) inden-7-onas 1,2-sustituidas y benzo (b) (1,4)dioxepin-3 onas 7-sustituidas.
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application